Atazanavir/ritonavir versus lopinavir/ritonavir: equivalent or different efficacy profiles?

被引：3
作者：
Hill, A [1 ]
机构：
[1] Univ Liverpool, Dept Pharmacol, Liverpool L69 3BX, Merseyside, England
来源：
AIDS | 2005年 / 19卷 / 17期
关键词：
D O I：
10.1097/01.aids.0000194137.73876.d5
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：2054 / 2055
页数：2
相关论文
共 5 条
[1]  
Food & Drug Administration, 2002, GUID IND ANT DRUGS U
[2]  
Gazzard B., 2004, 44 INT C ANT AG CHEM
[3]   Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection [J].
Gulick, RM ;
Ribaudo, HJ ;
Shikuma, CM ;
Lustgarten, S ;
Squires, KE ;
Meyer, WA ;
Acosta, EP ;
Schackman, BR ;
Pilcher, CD ;
Murphy, RL ;
Maher, WE ;
Witt, MD ;
Reichman, RC ;
Snyder, S ;
Klingman, KL ;
Kuritzkes, DR .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (18) :1850-1861
[4]   Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures [J].
Johnson, M ;
Grinsztejn, B ;
Rodriguez, C ;
Coco, J ;
DeJesus, E ;
Lazzarin, A ;
Lichtenstein, K ;
Rightmire, A ;
Sankoh, S ;
Wilber, R .
AIDS, 2005, 19 (07) :685-694
[5]  
*ROCH PHARM TRIM, 2004, US PRESCR INF
1